Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Key Highlights
- ➤Kamada launched Ustekinumab-Kamada and Enoxaparin-Kamada biosimilars in Israel
- ➤Biosimilar portfolio sales expected at approximately $4 million in 2026
- ➤Portfolio sales projected at approximately $10 million in 2028
- ➤Kamada expects at least 12 marketed biosimilars and $20 million-$25 million annual revenue by 2030
- ➤At least two additional biosimilar products expected commercially available during 2027
Expert Statements
Amir London, Chief Executive Officer of Kamada
“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars.”
Amir London, Chief Executive Officer of Kamada
“The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”
REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.
The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.
Get started
Create a free account to read the full story.